The worlds #1 website for end of day & historical stock data
wide range of exchanges, data formats, tools and services
API
NEW
HISTORICAL DATA
SYMBOL LISTS
MEMBERSHIP
REGISTER
LOG IN
Toggle navigation
HOME
Home Page
Download
Symbol Lists
Quote & Chart
Symbol Changes
Splits
Dividends
PRODUCTS & SERVICES
Membership Levels
Conversion Utility
API Service
Data Client
Historical Data
Fundamental Data
Commercial Feeds
Web Service
HOW TO
Advanced Get
AIQ
AMIBroker
EzyChart
MetaStock
OmniTrader
SuperCharts
TradeStation
SUPPORT
FAQ
Data Formats
Data Quality
Forgotten Password
Submit a Support Request
ABOUT
About Us
Contact Us
Terms & Conditions
Privacy Policy
Useful Links
MY ACCOUNT
Downloads
Account Details
API
Buy Historical Data
Billing History
Data Format
Daily Emails
Watchlists
FRA, 3NK: ALPHAMAB ONCOLO.DL-000002
04 Sep 2025
LAST:
1.020
CHANGE:
0.01
OPEN:
1.020
HIGH:
1.020
ASK:
0.000
VOLUME:
400
CHG(%):
0.99
PREV:
1.010
LOW:
1.020
BID:
0.000
CHART
Period:
End of Day
Weekly
Monthly
Yearly
RECENT END OF DAY PRICES
Date
Open
High
Low
Close
Volume
04 Sep 25
1.020
1.020
1.020
1.020
400
03 Sep 25
1.010
1.010
1.010
1.010
400
02 Sep 25
0.980
0.980
0.980
0.980
400
01 Sep 25
1.040
1.040
1.040
1.040
400
29 Aug 25
1.020
1.020
1.020
1.020
400
28 Aug 25
1.000
1.030
1.000
1.030
400
27 Aug 25
1.100
1.100
1.100
1.100
1
26 Aug 25
1.140
1.140
1.140
1.140
1
25 Aug 25
1.190
1.200
1.190
1.200
1
22 Aug 25
1.070
1.070
1.070
1.070
18
COMPANY PROFILE
Name:
ALPHAMAB ONCOLO.DL-000002
About:
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of advanced malignant solid tumors, lung cancer, and breast cancer; KN019, an immunosuppressive agent in Phase II clinical trial for prophylaxis of organ rejection in adult patients receiving a kidney transplant; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops pre-clinical stage products for oncology comprising JSKN022, JSKN027, JSKN021, JSKN020, and JSKN028 for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Sector:
Healthcare
Industry:
Biotechnology
Address:
No. 175 Fangzhou Road, Suzhou, China, 215127
Website:
https://www.alphamabonc.com
ISIN:
KYG0330A1013
SYMBOL HISTORY
Purchase End of Day History
for this symbol from Jan 01, 0001
Add to Watchlist
ADD TO WATCHLIST
Please select which Watchlist you would like to add this symbol to:
Watchlist:
DOWNLOAD DATA
Download stock quote history quickly and easily in a variety of formats to suit your needs.
Exchange:
American Stock Exchange
Australian Securities Exchange
Chicago Futures Exchange
Cryptocurrencies
EUREX Futures Exchange
Euronext - Amsterdam
Euronext - Brussels
Euronext - Lisbon
Euronext - Oslo
Euronext - Paris
Foreign Exchange
Frankfurt Exchange
Global Indices
LIFFE Futures and Options
London Stock Exchange
Madrid Stock Exchange
Minneapolis Grain Exchange
Mutual Funds
NASDAQ Stock Exchange
National Stock Exchange of India
New York Board of Trade
New York Stock Exchange
OTC Bulletin Board
Shanghai Stock Exchange
Shenzhen Stock Exchange
Singapore Stock Exchange
Toronto Stock Exchange
Toronto Venture Exchange
Winnipeg Commodity Exchange
Format:
3F VIP Trading
Advanced Get ASCII
AGet ASCII
AIQ Trading Expert Pro
Ami Broker
Ami Broker with Names
Andromeda
ASCII (Intraday)
EzyCharts
FCharts
FCharts (Intraday)
MetaStock ASCII (7 column)
MetaStock ASCII (8 column)
Metastock ASCII (Intraday)
MetaStock ASCII with Names
Personal Stock Streamer
Quicken
SpiffyCharts
Spreadsheet (eg: Excel)
Standard CSV
Stock Screener Pro
SuperCharts ASCII
Wal Data Platinum
Windows on Wallstreet
Period:
End of Day
1 Minute Bars
5 Minute Bars
10 Minute Bars
15 Minute Bars
30 Minute Bars
60 Minute Bars
Zip file
Symbol:
Start Date:
End Date:
Download
FUNDAMENTALS
P/E Ratio:
33.67
Price to Book:
4.29
Price to Sales:
1.37
EBITDA:
253.8M
Shares:
971.2M
Market Cap:
990.62M
TECHNICAL INDICATORS
MA5:
1.01
MA10:
1.06
MA20:
1.03
MA50:
0.93
MA100:
0.88
MA200:
0.71
STO9:
18.18
STO14:
18.18
RSI14:
53.78
WPR14:
-81.82
MTM14:
-0.01
ROC14:
-0.01
ATR:
0.04
Week High:
1.04
Week Low:
0.98
Month High:
1.20
Month Low:
0.94
Year High:
1.20
Year Low:
0.22
Volatility:
17.52